Nanopublications

Matches in Nanopublications for { ?s <http://purl.org/dc/terms/description> ?o ?g. }

Showing items 1,501 to 1,600 of ±4,848,813 with 100 items per page.

first
previous
next

NP205206.RAIa27-sfV3DmvaMl8HASAejy5iq7XPpdZjIY_TjHW85k130_assertion description "[increased alpha (2) -macroglobulin expression appears to be associated with benign prostatic hyperplasia]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP205206.RAIa27-sfV3DmvaMl8HASAejy5iq7XPpdZjIY_TjHW85k130_provenance.
assertion description "[Clonal variation in the production of tumor-associated alpha 2-macroglobulin in a malignant human melanoma and association with growth stimulation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP217232.RAZW6B56QgiiPlI7nV20oLaHVUKltkI7lLgaD_TPwn9IE130_assertion description "[Clonal variation in the production of tumor-associated alpha 2-macroglobulin in a malignant human melanoma and association with growth stimulation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217232.RAZW6B56QgiiPlI7nV20oLaHVUKltkI7lLgaD_TPwn9IE130_provenance.
NP939597.RAOQBmBxRl-SNldxWaRXUGdt28IpL1RdFAWKrDocEJ0J0130_assertion description "[Clonal variation in the production of tumor-associated alpha 2-macroglobulin in a malignant human melanoma and association with growth stimulation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP939597.RAOQBmBxRl-SNldxWaRXUGdt28IpL1RdFAWKrDocEJ0J0130_provenance.
NP1164837.RAlnHKrS_Llzp9fSnmHt35AArfrqEHu1OKWiM60gIm8Yk130_assertion description "[Clonal variation in the production of tumor-associated alpha 2-macroglobulin in a malignant human melanoma and association with growth stimulation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1164837.RAlnHKrS_Llzp9fSnmHt35AArfrqEHu1OKWiM60gIm8Yk130_provenance.
assertion description "[Coexpression of tumor-associated alpha 2-macroglobulin and growth factors in human melanoma cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP569534.RAjuIzVprh7WbzuMQVPa6I7Q8QlNX5iYFKOCjsH-g9fgM130_assertion description "[Coexpression of tumor-associated alpha 2-macroglobulin and growth factors in human melanoma cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP569534.RAjuIzVprh7WbzuMQVPa6I7Q8QlNX5iYFKOCjsH-g9fgM130_provenance.
NP217231.RAGWQoiSEG6UqZdf8W_Oi-RBT_5dH6Ey102wIK5Ce6hJE130_assertion description "[Coexpression of tumor-associated alpha 2-macroglobulin and growth factors in human melanoma cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217231.RAGWQoiSEG6UqZdf8W_Oi-RBT_5dH6Ey102wIK5Ce6hJE130_provenance.
assertion description "[alpha 2-macroglobulin production by cultured human melanoma cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP217233.RAycuJ8R6OwKxuRBiN4Orq90-NveWkwtXuqF3qTKEUMi4130_assertion description "[alpha 2-macroglobulin production by cultured human melanoma cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217233.RAycuJ8R6OwKxuRBiN4Orq90-NveWkwtXuqF3qTKEUMi4130_provenance.
NP1305085.RAIektj1JwGjMpP3hFOWUIWAKe4VwVS1ioiwfRvxy_jd8130_assertion description "[alpha 2-macroglobulin production by cultured human melanoma cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1305085.RAIektj1JwGjMpP3hFOWUIWAKe4VwVS1ioiwfRvxy_jd8130_provenance.
assertion description "[In addition, when elevated alpha2MG levels > 90th percentile were compared with values below the cut-off, including established prothrombotic risk factors in the multivariate analysis, patients had a significantly increased OR/95% CI for fibrinogen-adjusted alpha2MG levels (IS, 5.9/1.9-18.3; DVT, 7.2/2.1-24.4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[In addition, when elevated alpha2MG levels > 90th percentile were compared with values below the cut-off, including established prothrombotic risk factors in the multivariate analysis, patients had a significantly increased OR/95% CI for fibrinogen-adjusted alpha2MG levels (IS, 5.9/1.9-18.3; DVT, 7.2/2.1-24.4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP217278.RAaUdXV6es3HH0rCLRAvRWO1D2qxizEv0O3ZZfP0gqU2k130_assertion description "[In addition, when elevated alpha2MG levels > 90th percentile were compared with values below the cut-off, including established prothrombotic risk factors in the multivariate analysis, patients had a significantly increased OR/95% CI for fibrinogen-adjusted alpha2MG levels (IS, 5.9/1.9-18.3; DVT, 7.2/2.1-24.4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217278.RAaUdXV6es3HH0rCLRAvRWO1D2qxizEv0O3ZZfP0gqU2k130_provenance.
NP602188.RAgWXDrqGzJ1mG6Gy0Yjn2JST-yGEk4p6SCYz4L9ICB64130_assertion description "[In addition, when elevated alpha2MG levels > 90th percentile were compared with values below the cut-off, including established prothrombotic risk factors in the multivariate analysis, patients had a significantly increased OR/95% CI for fibrinogen-adjusted alpha2MG levels (IS, 5.9/1.9-18.3; DVT, 7.2/2.1-24.4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP602188.RAgWXDrqGzJ1mG6Gy0Yjn2JST-yGEk4p6SCYz4L9ICB64130_provenance.
NP217266.RAx0rliaQ9oGt8HZY6GzXzioxl02KwaNt0sZNRC1Ky1lA130_assertion description "[In addition, when elevated alpha2MG levels > 90th percentile were compared with values below the cut-off, including established prothrombotic risk factors in the multivariate analysis, patients had a significantly increased OR/95% CI for fibrinogen-adjusted alpha2MG levels (IS, 5.9/1.9-18.3; DVT, 7.2/2.1-24.4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217266.RAx0rliaQ9oGt8HZY6GzXzioxl02KwaNt0sZNRC1Ky1lA130_provenance.
NP602186.RA_Wo2aUJd9xiL5zeV9B7I11CrmYfwx3VrNV42kmozZA8130_assertion description "[In addition, when elevated alpha2MG levels > 90th percentile were compared with values below the cut-off, including established prothrombotic risk factors in the multivariate analysis, patients had a significantly increased OR/95% CI for fibrinogen-adjusted alpha2MG levels (IS, 5.9/1.9-18.3; DVT, 7.2/2.1-24.4).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP602186.RA_Wo2aUJd9xiL5zeV9B7I11CrmYfwx3VrNV42kmozZA8130_provenance.
assertion description "[Detection of an alteration of the alpha 2-macroglobulin gene in a patient with chronic lung disease and serum alpha 2-macroglobulin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[Detection of an alteration of the alpha 2-macroglobulin gene in a patient with chronic lung disease and serum alpha 2-macroglobulin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP7177.RAaUAM33M_BTOLdE5msfz7N-bgnT-gYurNppYwZmjbpuo130_assertion description "[Detection of an alteration of the alpha 2-macroglobulin gene in a patient with chronic lung disease and serum alpha 2-macroglobulin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP7177.RAaUAM33M_BTOLdE5msfz7N-bgnT-gYurNppYwZmjbpuo130_provenance.
NP217264.RAX6Rhq1_DTwp-bexCBPzgFPQvySUux2zlwNVgV--KwPQ130_assertion description "[Detection of an alteration of the alpha 2-macroglobulin gene in a patient with chronic lung disease and serum alpha 2-macroglobulin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217264.RAX6Rhq1_DTwp-bexCBPzgFPQvySUux2zlwNVgV--KwPQ130_provenance.
NP1175608.RACQgtI3PXMNQYJSpEXUteDtpc1gcztCSZIGApqYBuAEI130_assertion description "[Detection of an alteration of the alpha 2-macroglobulin gene in a patient with chronic lung disease and serum alpha 2-macroglobulin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175608.RACQgtI3PXMNQYJSpEXUteDtpc1gcztCSZIGApqYBuAEI130_provenance.
NP835361.RANE0DDK8lV2rFvjZiD1gxMq_jT4eSRaJDmVFew37ln5I130_assertion description "[Detection of an alteration of the alpha 2-macroglobulin gene in a patient with chronic lung disease and serum alpha 2-macroglobulin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP835361.RANE0DDK8lV2rFvjZiD1gxMq_jT4eSRaJDmVFew37ln5I130_provenance.
NP217279.RA4mIMayQrwGr3M_M0M6KBkvYslQSCxdM_bz07_a9GUnw130_assertion description "[Detection of an alteration of the alpha 2-macroglobulin gene in a patient with chronic lung disease and serum alpha 2-macroglobulin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217279.RA4mIMayQrwGr3M_M0M6KBkvYslQSCxdM_bz07_a9GUnw130_provenance.
NP34006.RA34huYWcM7ivo0IJL_-LPFc0YL_Rz3_cYQFBgGUI497c130_assertion description "[Detection of an alteration of the alpha 2-macroglobulin gene in a patient with chronic lung disease and serum alpha 2-macroglobulin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP34006.RA34huYWcM7ivo0IJL_-LPFc0YL_Rz3_cYQFBgGUI497c130_provenance.
NP1175606.RAwGzMIG1rqxHsvAdQRA8qbd0BfYHC94Hq_xPW8Vemmqs130_assertion description "[Detection of an alteration of the alpha 2-macroglobulin gene in a patient with chronic lung disease and serum alpha 2-macroglobulin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175606.RAwGzMIG1rqxHsvAdQRA8qbd0BfYHC94Hq_xPW8Vemmqs130_provenance.
assertion description "[No association of three polymorphisms in the alpha-2-macroglobulin and lipoprotein related receptor genes with multiple sclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP217234.RAUf_a6wzau4FR9HUjYaEW7gzyZAKSmuhtwU_iZyfYAi8130_assertion description "[No association of three polymorphisms in the alpha-2-macroglobulin and lipoprotein related receptor genes with multiple sclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217234.RAUf_a6wzau4FR9HUjYaEW7gzyZAKSmuhtwU_iZyfYAi8130_provenance.
NP326722.RAc3iQmIsdEfPl0gSnkyLWLeduKnn2Skz4PA-BVLIW0Vc130_assertion description "[No association of three polymorphisms in the alpha-2-macroglobulin and lipoprotein related receptor genes with multiple sclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP326722.RAc3iQmIsdEfPl0gSnkyLWLeduKnn2Skz4PA-BVLIW0Vc130_provenance.
assertion description "[an important involvement of alpha2M in regulation of increased proteolytic activity occurring in multiple sclerosis disease]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP773556.RAsnY7bO9kiefn-F4GG3rDUGFaQUkcxUlZ-xWCWhdZO8U130_assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773556.RAsnY7bO9kiefn-F4GG3rDUGFaQUkcxUlZ-xWCWhdZO8U130_provenance.
assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP359850.RACxHZdxGRwsPHLNll8vct56acV22LQtEE_0Cx2rHpTxA130_assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP359850.RACxHZdxGRwsPHLNll8vct56acV22LQtEE_0Cx2rHpTxA130_provenance.
NP309566.RAmT9yXdiNpWZiQAjO8sIluJ8IUvqC2NcDMNtP9r6kuCM130_assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP309566.RAmT9yXdiNpWZiQAjO8sIluJ8IUvqC2NcDMNtP9r6kuCM130_provenance.
NP539626.RA8JZSeUYxjiOXZUK2glIVY5t6bibNM0o1H_m2CfATGKA130_assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP539626.RA8JZSeUYxjiOXZUK2glIVY5t6bibNM0o1H_m2CfATGKA130_provenance.
NP420060.RAPhzM6uaqwiCWq05lTUi5Ei94NkO1pMR0ukQIiedy66o130_assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP420060.RAPhzM6uaqwiCWq05lTUi5Ei94NkO1pMR0ukQIiedy66o130_provenance.
assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP217280.RAkjF99J5qlYKpu-d84ID-iTN6EoYimyrYRY5AqrnpZN8130_assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217280.RAkjF99J5qlYKpu-d84ID-iTN6EoYimyrYRY5AqrnpZN8130_provenance.
NP1304959.RAe1rv8P34AvRHVkinWsirDXPj0ZSpbNv1tLXKjaU1i4A130_assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1304959.RAe1rv8P34AvRHVkinWsirDXPj0ZSpbNv1tLXKjaU1i4A130_provenance.
NP1304961.RAdjWe6I9xCqfsik3MB_6LdvIalRPe1uXrv1A12muKv7g130_assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1304961.RAdjWe6I9xCqfsik3MB_6LdvIalRPe1uXrv1A12muKv7g130_provenance.
NP1304962.RAWfg0CFw3yS0X4epd9bIbi5RzIWqJ2YXcldC748O53Ms130_assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1304962.RAWfg0CFw3yS0X4epd9bIbi5RzIWqJ2YXcldC748O53Ms130_provenance.
NP1304960.RAvbJip05U4knblEP_ZZ1oCty7yH_fhjzl8OjxYgno5RI130_assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1304960.RAvbJip05U4knblEP_ZZ1oCty7yH_fhjzl8OjxYgno5RI130_provenance.
NP217247.RA5Ka8JdfpEcM5iMYHygtVGXnZ8QawuPIa9pdMSxQo53A130_assertion description "[These studies demonstrated that: (a) alpha 1-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) alpha 2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ alpha 1-antitrypsin deficiency have little or no alpha 1-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217247.RA5Ka8JdfpEcM5iMYHygtVGXnZ8QawuPIa9pdMSxQo53A130_provenance.
assertion description "[alpha 2-Macroglobulin in patients with obstructive lung disease, with and without alpha 1-antitrypsin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[alpha 2-Macroglobulin in patients with obstructive lung disease, with and without alpha 1-antitrypsin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[alpha 2-Macroglobulin in patients with obstructive lung disease, with and without alpha 1-antitrypsin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP751377.RAkdSh-5OWYZs8S4VwuiyRP7zvdbPPyjdxTTfOTtZL0RE130_assertion description "[alpha 2-Macroglobulin in patients with obstructive lung disease, with and without alpha 1-antitrypsin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP751377.RAkdSh-5OWYZs8S4VwuiyRP7zvdbPPyjdxTTfOTtZL0RE130_provenance.
NP365735.RANHZkvem4fe9Aeb6IE5OIBt8A-IB2hn_xO_tKq9S4VTs130_assertion description "[alpha 2-Macroglobulin in patients with obstructive lung disease, with and without alpha 1-antitrypsin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP365735.RANHZkvem4fe9Aeb6IE5OIBt8A-IB2hn_xO_tKq9S4VTs130_provenance.
NP217248.RAYXMlm-17smVdFR2PMWthHBwvk34dBwTU2PylzGhyJe4130_assertion description "[alpha 2-Macroglobulin in patients with obstructive lung disease, with and without alpha 1-antitrypsin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217248.RAYXMlm-17smVdFR2PMWthHBwvk34dBwTU2PylzGhyJe4130_provenance.
NP217281.RArr22CmDPJpGjN3HCSQbTeohHk9HKmPwoVVuqfjGireo130_assertion description "[alpha 2-Macroglobulin in patients with obstructive lung disease, with and without alpha 1-antitrypsin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217281.RArr22CmDPJpGjN3HCSQbTeohHk9HKmPwoVVuqfjGireo130_provenance.
NP1305032.RAVUd86Jsocrd5PlOEt1uKBzNuHMEo5KZa0oquHbUWH18130_assertion description "[alpha 2-Macroglobulin in patients with obstructive lung disease, with and without alpha 1-antitrypsin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1305032.RAVUd86Jsocrd5PlOEt1uKBzNuHMEo5KZa0oquHbUWH18130_provenance.
NP1305035.RARrXFFIBd7DvAc3L4A-o-S9DHb1XYspdrC6Ew2sPt0XQ130_assertion description "[alpha 2-Macroglobulin in patients with obstructive lung disease, with and without alpha 1-antitrypsin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1305035.RARrXFFIBd7DvAc3L4A-o-S9DHb1XYspdrC6Ew2sPt0XQ130_provenance.
NP1305029.RAj5bzeWRtFAOIgVoYOPL3ub2EE0fOSJj1XmKsgIfoKm4130_assertion description "[alpha 2-Macroglobulin in patients with obstructive lung disease, with and without alpha 1-antitrypsin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1305029.RAj5bzeWRtFAOIgVoYOPL3ub2EE0fOSJj1XmKsgIfoKm4130_provenance.
NP217263.RA24-TCH5-37TAkPB88CPLizGGXP8IubxLdv_nUx6jnqg130_assertion description "[alpha 2-Macroglobulin in patients with obstructive lung disease, with and without alpha 1-antitrypsin deficiency.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217263.RA24-TCH5-37TAkPB88CPLizGGXP8IubxLdv_nUx6jnqg130_provenance.
NP55185.RAnCYcTImrbM8k66Xc63yW79n4EyWS_B9QRCTZlQD3N-Y130_assertion description "[According to our data, the variation at the LRPAP1 gene could contribute to the risk of developing an early episode of MI.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP55185.RAnCYcTImrbM8k66Xc63yW79n4EyWS_B9QRCTZlQD3N-Y130_provenance.
assertion description "[According to our data, the variation at the LRPAP1 gene could contribute to the risk of developing an early episode of MI.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP169295.RA0qlafTdNdPG_KprZg0mlWAeEVKJUlXur8rU8yU7SHWs130_assertion description "[According to our data, the variation at the LRPAP1 gene could contribute to the risk of developing an early episode of MI.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP169295.RA0qlafTdNdPG_KprZg0mlWAeEVKJUlXur8rU8yU7SHWs130_provenance.
assertion description "[According to our data, the variation at the LRPAP1 gene could contribute to the risk of developing an early episode of MI.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[OSM levels in lysates of nasal polyps and uncinate tissue positively correlated with levels of ?2-macroglobulin, a marker of epithelial leak, in localized nasal secretions (r?= 0.4855, P?< .05).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[OSM levels in lysates of nasal polyps and uncinate tissue positively correlated with levels of ?2-macroglobulin, a marker of epithelial leak, in localized nasal secretions (r?= 0.4855, P?< .05).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[Likewise, mutations that weaken the A2M-APP (amyloid precursor protein) association may increase the proliferative effect of APP through preventing ?-amyloid degradation by the A2M receptor, and mutations that abolish the A2M-Kallikrein-13 (KLK13) interaction may lead to cell proliferation and metastasis through the destructive effect of KLK13 on the extracellular matrix.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[Likewise, mutations that weaken the A2M-APP (amyloid precursor protein) association may increase the proliferative effect of APP through preventing ?-amyloid degradation by the A2M receptor, and mutations that abolish the A2M-Kallikrein-13 (KLK13) interaction may lead to cell proliferation and metastasis through the destructive effect of KLK13 on the extracellular matrix.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[Likewise, mutations that weaken the A2M-APP (amyloid precursor protein) association may increase the proliferative effect of APP through preventing ?-amyloid degradation by the A2M receptor, and mutations that abolish the A2M-Kallikrein-13 (KLK13) interaction may lead to cell proliferation and metastasis through the destructive effect of KLK13 on the extracellular matrix.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP1204499.RAqlWfWXXeKxLdjjCp00JWUebHfpQE_tGeBQb8uDYSCVc130_assertion description "[Likewise, mutations that weaken the A2M-APP (amyloid precursor protein) association may increase the proliferative effect of APP through preventing ?-amyloid degradation by the A2M receptor, and mutations that abolish the A2M-Kallikrein-13 (KLK13) interaction may lead to cell proliferation and metastasis through the destructive effect of KLK13 on the extracellular matrix.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1204499.RAqlWfWXXeKxLdjjCp00JWUebHfpQE_tGeBQb8uDYSCVc130_provenance.
NP1204504.RAtQfn9kQgfcLr1wLLhidgb5x3Sp1CRi8IgnPVU6XGifs130_assertion description "[Likewise, mutations that weaken the A2M-APP (amyloid precursor protein) association may increase the proliferative effect of APP through preventing ?-amyloid degradation by the A2M receptor, and mutations that abolish the A2M-Kallikrein-13 (KLK13) interaction may lead to cell proliferation and metastasis through the destructive effect of KLK13 on the extracellular matrix.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1204504.RAtQfn9kQgfcLr1wLLhidgb5x3Sp1CRi8IgnPVU6XGifs130_provenance.
NP1204500.RA52WVhRQUvA2g38RDiZ6asmxHezvL3gKl2x1u0uaiNMY130_assertion description "[Likewise, mutations that weaken the A2M-APP (amyloid precursor protein) association may increase the proliferative effect of APP through preventing ?-amyloid degradation by the A2M receptor, and mutations that abolish the A2M-Kallikrein-13 (KLK13) interaction may lead to cell proliferation and metastasis through the destructive effect of KLK13 on the extracellular matrix.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1204500.RA52WVhRQUvA2g38RDiZ6asmxHezvL3gKl2x1u0uaiNMY130_provenance.
assertion description "[We have utilized in situ hybridization and immunocytochemistry techniques to examine the expression of both alpha 2-macroglobulin (alpha 2-MR) and the 39 kDa receptor-associated protein (RAP) in 8 benign (BPH) and 34 malignant human prostate tissues, including 4 metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP862997.RAqajHTXDm0tDp9EElo2z8kcoPa1x-tXW0DHVjHawCIfQ130_assertion description "[We have utilized in situ hybridization and immunocytochemistry techniques to examine the expression of both alpha 2-macroglobulin (alpha 2-MR) and the 39 kDa receptor-associated protein (RAP) in 8 benign (BPH) and 34 malignant human prostate tissues, including 4 metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP862997.RAqajHTXDm0tDp9EElo2z8kcoPa1x-tXW0DHVjHawCIfQ130_provenance.
NP427919.RAqXL5fRCG_ekW9ijGrPZlww2trCD7DM2UxIujlWYELGM130_assertion description "[We have utilized in situ hybridization and immunocytochemistry techniques to examine the expression of both alpha 2-macroglobulin (alpha 2-MR) and the 39 kDa receptor-associated protein (RAP) in 8 benign (BPH) and 34 malignant human prostate tissues, including 4 metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP427919.RAqXL5fRCG_ekW9ijGrPZlww2trCD7DM2UxIujlWYELGM130_provenance.
NP733795.RAjfEKJbRafG7gug7KtJq0Xn51WvZWMB5zL5zqNAXSL6I130_assertion description "[We have utilized in situ hybridization and immunocytochemistry techniques to examine the expression of both alpha 2-macroglobulin (alpha 2-MR) and the 39 kDa receptor-associated protein (RAP) in 8 benign (BPH) and 34 malignant human prostate tissues, including 4 metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP733795.RAjfEKJbRafG7gug7KtJq0Xn51WvZWMB5zL5zqNAXSL6I130_provenance.
NP525713.RA7F4uT1iJdYt9o-ZS2k9bXdcZZfcz-JNYueY4q3l0gco130_assertion description "[We have utilized in situ hybridization and immunocytochemistry techniques to examine the expression of both alpha 2-macroglobulin (alpha 2-MR) and the 39 kDa receptor-associated protein (RAP) in 8 benign (BPH) and 34 malignant human prostate tissues, including 4 metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP525713.RA7F4uT1iJdYt9o-ZS2k9bXdcZZfcz-JNYueY4q3l0gco130_provenance.
NP556955.RA6gYVGN11QVvOkcsOfzGiRruYKsvryPwGPkCWqUtn5mw130_assertion description "[We have utilized in situ hybridization and immunocytochemistry techniques to examine the expression of both alpha 2-macroglobulin (alpha 2-MR) and the 39 kDa receptor-associated protein (RAP) in 8 benign (BPH) and 34 malignant human prostate tissues, including 4 metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP556955.RA6gYVGN11QVvOkcsOfzGiRruYKsvryPwGPkCWqUtn5mw130_provenance.
NP845321.RAzx08REYfga7FbA50yjOmKnLzSmIjnKmerqwpOrdTZN4130_assertion description "[We have utilized in situ hybridization and immunocytochemistry techniques to examine the expression of both alpha 2-macroglobulin (alpha 2-MR) and the 39 kDa receptor-associated protein (RAP) in 8 benign (BPH) and 34 malignant human prostate tissues, including 4 metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP845321.RAzx08REYfga7FbA50yjOmKnLzSmIjnKmerqwpOrdTZN4130_provenance.
NP1348016.RAmF-q7vrVbcJjh04Xzxua4aFcvr9GMx6h0LfwaEoRW9w130_assertion description "[We have utilized in situ hybridization and immunocytochemistry techniques to examine the expression of both alpha 2-macroglobulin (alpha 2-MR) and the 39 kDa receptor-associated protein (RAP) in 8 benign (BPH) and 34 malignant human prostate tissues, including 4 metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1348016.RAmF-q7vrVbcJjh04Xzxua4aFcvr9GMx6h0LfwaEoRW9w130_provenance.
NP217235.RA2COOq78bCqCjOPJT0rA5k6LnBzoE6-0bWurCfJo2-z8130_assertion description "[We have utilized in situ hybridization and immunocytochemistry techniques to examine the expression of both alpha 2-macroglobulin (alpha 2-MR) and the 39 kDa receptor-associated protein (RAP) in 8 benign (BPH) and 34 malignant human prostate tissues, including 4 metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217235.RA2COOq78bCqCjOPJT0rA5k6LnBzoE6-0bWurCfJo2-z8130_provenance.
NP217276.RAwpvNxuGw3ARfvG2ejcXxFB66ysXcoht18avxm5QDUKQ130_assertion description "[We have utilized in situ hybridization and immunocytochemistry techniques to examine the expression of both alpha 2-macroglobulin (alpha 2-MR) and the 39 kDa receptor-associated protein (RAP) in 8 benign (BPH) and 34 malignant human prostate tissues, including 4 metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217276.RAwpvNxuGw3ARfvG2ejcXxFB66ysXcoht18avxm5QDUKQ130_provenance.
assertion description "[?2-Macroglobulin (?2M) is thought to be involved in cancer metastasis and inflammatory reaction through its functions as a proteinase inhibitor and carrier protein for interleukin-6 (IL-6).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP825867.RA4uefj8CfoYIawQ2bnXO5UC7cg9Y5vuSgH1ui3-GLSLA130_assertion description "[?2-Macroglobulin (?2M) is thought to be involved in cancer metastasis and inflammatory reaction through its functions as a proteinase inhibitor and carrier protein for interleukin-6 (IL-6).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP825867.RA4uefj8CfoYIawQ2bnXO5UC7cg9Y5vuSgH1ui3-GLSLA130_provenance.
assertion description "[?2-Macroglobulin (?2M) is thought to be involved in cancer metastasis and inflammatory reaction through its functions as a proteinase inhibitor and carrier protein for interleukin-6 (IL-6).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP646615.RALbG6VwtLrKnvK0v3K3RxcBaM0-PhNx-NgcBQfPblU10130_assertion description "[?2-Macroglobulin (?2M) is thought to be involved in cancer metastasis and inflammatory reaction through its functions as a proteinase inhibitor and carrier protein for interleukin-6 (IL-6).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646615.RALbG6VwtLrKnvK0v3K3RxcBaM0-PhNx-NgcBQfPblU10130_provenance.
NP217211.RAk6uVxHCgtXeoT3FixdP3N-hLJm9XcmoAKdu0RmE8GKU130_assertion description "[?2-Macroglobulin (?2M) is thought to be involved in cancer metastasis and inflammatory reaction through its functions as a proteinase inhibitor and carrier protein for interleukin-6 (IL-6).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217211.RAk6uVxHCgtXeoT3FixdP3N-hLJm9XcmoAKdu0RmE8GKU130_provenance.
NP217277.RA1O6ZHNICCnRP0-0ifrpCIAJTkF9p6bTwrTJgaQzjrm4130_assertion description "[?2-Macroglobulin (?2M) is thought to be involved in cancer metastasis and inflammatory reaction through its functions as a proteinase inhibitor and carrier protein for interleukin-6 (IL-6).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217277.RA1O6ZHNICCnRP0-0ifrpCIAJTkF9p6bTwrTJgaQzjrm4130_provenance.
NP981219.RArxtu9-5BSVy8ziCOHuR1VmjpE6lZLUHTFkeAoiVLGDM130_assertion description "[?2-Macroglobulin (?2M) is thought to be involved in cancer metastasis and inflammatory reaction through its functions as a proteinase inhibitor and carrier protein for interleukin-6 (IL-6).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP981219.RArxtu9-5BSVy8ziCOHuR1VmjpE6lZLUHTFkeAoiVLGDM130_provenance.
NP981220.RAms8UtIK1UD9XEBiQrckcPHKu5df5WpE0b6cJOJBivG4130_assertion description "[?2-Macroglobulin (?2M) is thought to be involved in cancer metastasis and inflammatory reaction through its functions as a proteinase inhibitor and carrier protein for interleukin-6 (IL-6).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP981220.RAms8UtIK1UD9XEBiQrckcPHKu5df5WpE0b6cJOJBivG4130_provenance.
NP217236.RAFR56rsKvXsSfjM99ZcZEY-M2KzH1gr2sixKMT2EzIwc130_assertion description "[?2-Macroglobulin (?2M) is thought to be involved in cancer metastasis and inflammatory reaction through its functions as a proteinase inhibitor and carrier protein for interleukin-6 (IL-6).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217236.RAFR56rsKvXsSfjM99ZcZEY-M2KzH1gr2sixKMT2EzIwc130_provenance.
NP217267.RAEctu5-RbwLYLKjsg9HA2fhOBkdHPC_vg7mGRDiEzghs130_assertion description "[?2-Macroglobulin (?2M) is thought to be involved in cancer metastasis and inflammatory reaction through its functions as a proteinase inhibitor and carrier protein for interleukin-6 (IL-6).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217267.RAEctu5-RbwLYLKjsg9HA2fhOBkdHPC_vg7mGRDiEzghs130_provenance.
NP29341.RA8GXz9rQWt6Q6pBLXOaTEzq8I0rzYGfAHAwog0EYHwgc130_assertion description "[We studied plasma antithrombin III (AT-III), alpha 1-PI, alpha 2-antiplasmin (alpha 2-A), alpha 2-macroglobulin (alpha 2-M) activity, and some blood coagulation and fibrinolysis tests in children with frequently relapsing prednisone-responsive NS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP29341.RA8GXz9rQWt6Q6pBLXOaTEzq8I0rzYGfAHAwog0EYHwgc130_provenance.
assertion description "[We studied plasma antithrombin III (AT-III), alpha 1-PI, alpha 2-antiplasmin (alpha 2-A), alpha 2-macroglobulin (alpha 2-M) activity, and some blood coagulation and fibrinolysis tests in children with frequently relapsing prednisone-responsive NS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[We studied plasma antithrombin III (AT-III), alpha 1-PI, alpha 2-antiplasmin (alpha 2-A), alpha 2-macroglobulin (alpha 2-M) activity, and some blood coagulation and fibrinolysis tests in children with frequently relapsing prednisone-responsive NS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP5251.RA9ppa9duusULKA01ZaGGgNL51oshcIxzF8sNP8vJccUA130_assertion description "[We studied plasma antithrombin III (AT-III), alpha 1-PI, alpha 2-antiplasmin (alpha 2-A), alpha 2-macroglobulin (alpha 2-M) activity, and some blood coagulation and fibrinolysis tests in children with frequently relapsing prednisone-responsive NS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP5251.RA9ppa9duusULKA01ZaGGgNL51oshcIxzF8sNP8vJccUA130_provenance.
NP29462.RAlMOX2HWXCjO6I6bvCU8gnX1jXqJ1EzbxxfpEC6GCapg130_assertion description "[We studied plasma antithrombin III (AT-III), alpha 1-PI, alpha 2-antiplasmin (alpha 2-A), alpha 2-macroglobulin (alpha 2-M) activity, and some blood coagulation and fibrinolysis tests in children with frequently relapsing prednisone-responsive NS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP29462.RAlMOX2HWXCjO6I6bvCU8gnX1jXqJ1EzbxxfpEC6GCapg130_provenance.
assertion description "[The serum alpha 2M concentration was increased approximately equal to 50-fold and was proportional to synthesis (r = 0.91 P < 0.001). alpha 2-Macroglobulin synthesis increased by 12-fold in NAR and 50-fold in NS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP66961.RAaO0ouy4Flu6gAPNgNnx82jBySRfPRvZuELqamGij08I130_assertion description "[The serum alpha 2M concentration was increased approximately equal to 50-fold and was proportional to synthesis (r = 0.91 P < 0.001). alpha 2-Macroglobulin synthesis increased by 12-fold in NAR and 50-fold in NS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP66961.RAaO0ouy4Flu6gAPNgNnx82jBySRfPRvZuELqamGij08I130_provenance.
assertion description "[The genetic association between alpha-2-macroglobulin (A2M) gene deletion polymorphism and low serum A2M concentration in overweight/obese Thais.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
assertion description "[The genetic association between alpha-2-macroglobulin (A2M) gene deletion polymorphism and low serum A2M concentration in overweight/obese Thais.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
NP673800.RACwvqMOph7bz3SLa4NKslxbwKBJA6qFJqkrThzkBPD1c130_assertion description "[Testing a subset of these plasma proteins in macrophage stimulation assays, we found that Gc-globulin, ?1-microglobulin, and ?2-macroglobulin can signal via TLR4 to induce macrophage production of inflammatory cytokines implicated in OA.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP673800.RACwvqMOph7bz3SLa4NKslxbwKBJA6qFJqkrThzkBPD1c130_provenance.

first
previous
next